Relay Therapeutics (RLAY) Competitors $3.62 +0.01 (+0.14%) Closing price 03:59 PM EasternExtended Trading$3.64 +0.02 (+0.41%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLAY vs. AMRX, OGN, APLS, XENE, IBRX, BHC, AGIO, CNTA, BEAM, and TWSTShould you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), ImmunityBio (IBRX), Bausch Health Cos (BHC), Agios Pharmaceuticals (AGIO), Centessa Pharmaceuticals (CNTA), Beam Therapeutics (BEAM), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry. Relay Therapeutics vs. Its Competitors Amneal Pharmaceuticals Organon & Co. Apellis Pharmaceuticals Xenon Pharmaceuticals ImmunityBio Bausch Health Cos Agios Pharmaceuticals Centessa Pharmaceuticals Beam Therapeutics Twist Bioscience Relay Therapeutics (NASDAQ:RLAY) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership. Do analysts prefer RLAY or AMRX? Relay Therapeutics presently has a consensus target price of $17.67, suggesting a potential upside of 387.36%. Amneal Pharmaceuticals has a consensus target price of $11.60, suggesting a potential upside of 43.65%. Given Relay Therapeutics' higher probable upside, equities analysts plainly believe Relay Therapeutics is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.83Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, RLAY or AMRX? Amneal Pharmaceuticals has higher revenue and earnings than Relay Therapeutics. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelay Therapeutics$10.01M62.09-$337.71M-$2.23-1.63Amneal Pharmaceuticals$2.79B0.91-$116.89M-$0.04-201.88 Which has more risk & volatility, RLAY or AMRX? Relay Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Do institutionals & insiders have more ownership in RLAY or AMRX? 97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 4.3% of Relay Therapeutics shares are held by company insiders. Comparatively, 17.5% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is RLAY or AMRX more profitable? Relay Therapeutics has a net margin of 0.00% compared to Amneal Pharmaceuticals' net margin of -0.46%. Relay Therapeutics' return on equity of -44.17% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Relay TherapeuticsN/A -44.17% -39.53% Amneal Pharmaceuticals -0.46%-188.26%5.34% Does the media prefer RLAY or AMRX? In the previous week, Relay Therapeutics had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 5 mentions for Relay Therapeutics and 3 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.37 beat Relay Therapeutics' score of 0.93 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryRelay Therapeutics beats Amneal Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLAY vs. The Competition Export to ExcelMetricRelay TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$621.51M$2.46B$5.59B$9.53BDividend YieldN/A1.77%4.71%4.03%P/E Ratio-1.639.4927.9619.93Price / Sales62.09427.91389.5465.88Price / CashN/A165.5736.3258.75Price / Book0.784.968.375.77Net Income-$337.71M$31.62M$3.25B$259.10M7 Day Performance-4.35%-3.27%-2.50%-3.41%1 Month Performance4.77%9.78%7.98%8.53%1 Year Performance-56.17%-5.75%34.65%15.75% Relay Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLAYRelay Therapeutics2.1594 of 5 stars$3.63+0.1%$17.67+387.4%-55.9%$621.51M$10.01M-1.63330News CoverageUpcoming EarningsAMRXAmneal Pharmaceuticals2.9367 of 5 stars$7.91-0.8%$11.60+46.6%+10.2%$2.48B$2.79B-197.708,100News CoveragePositive NewsOGNOrganon & Co.4.8816 of 5 stars$9.43-0.4%$18.00+91.0%-54.9%$2.45B$6.40B3.274,000Positive NewsUpcoming EarningsAPLSApellis Pharmaceuticals4.385 of 5 stars$19.28-1.0%$40.00+107.5%-51.8%$2.42B$781.37M-10.77770Upcoming EarningsAnalyst ForecastAnalyst RevisionXENEXenon Pharmaceuticals3.7204 of 5 stars$31.49-0.3%$54.82+74.1%-29.6%$2.42B$9.43M-9.75210Positive NewsIBRXImmunityBio2.1753 of 5 stars$2.68-2.5%$12.25+357.1%-53.2%$2.37B$14.74M-4.62590BHCBausch Health Cos3.785 of 5 stars$6.34+0.4%$7.30+15.2%+14.8%$2.34B$9.63B-57.6020,700News CoverageAGIOAgios Pharmaceuticals4.3879 of 5 stars$39.92-0.2%$58.60+46.8%-20.5%$2.31B$37.04M3.55390News CoverageUpcoming EarningsAnalyst ForecastCNTACentessa Pharmaceuticals3.3572 of 5 stars$16.06+2.4%$28.10+75.0%+42.8%$2.14B$6.85M-8.87200Positive NewsBEAMBeam Therapeutics2.2946 of 5 stars$21.03+1.3%$48.75+131.8%-37.8%$2.11B$63.52M-4.56510Upcoming EarningsGap UpTWSTTwist Bioscience4.4795 of 5 stars$34.77-1.1%$50.40+45.0%-39.6%$2.08B$312.97M-10.70990Positive NewsUpcoming Earnings Related Companies and Tools Related Companies AMRX Alternatives OGN Alternatives APLS Alternatives XENE Alternatives IBRX Alternatives BHC Alternatives AGIO Alternatives CNTA Alternatives BEAM Alternatives TWST Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLAY) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredStrange Investment Secret Predicts Market's Next Move?A strange market signal discovered before the Great Depression has predicted nearly every major financial even...Weiss Ratings | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLAY Stock Alerts